A prospective open-label pilot trial of PS-341 (bortezomib; Velcade) for the therapy of symptomatic advanced myeloproliferative disorders

Trial Profile

A prospective open-label pilot trial of PS-341 (bortezomib; Velcade) for the therapy of symptomatic advanced myeloproliferative disorders

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelofibrosis; Systemic mastocytosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Mar 2011 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 29 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jul 2008 The expected completion date for this trial is now 1 Dec 2008, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top